Observational studies suggest that statin treatment has a fracture-preventive effect; however, there is only limited supporting evidence from randomized controlled trials. Now, results from the JUPITER trial show that rosuvastatin treatment does not reduce the risk of fractures and, further, that levels of high sensitivity C-reactive protein are not associated with fracture risk.
